- Home
- HGV vs RARE Comparison
HGV vs RARE Comparison
Compare HGV & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGV
- RARE
- Stock Information
- Founded
- HGV 1992
- RARE 2010
- Country
- HGV United States
- RARE United States
- Employees
- HGV N/A
- RARE N/A
- Industry
- HGV Hotels/Resorts
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- HGV Consumer Discretionary
- RARE Health Care
- Exchange
- HGV Nasdaq
- RARE Nasdaq
- Market Cap
- HGV 3.7B
- RARE 3.5B
- IPO Year
- HGV N/A
- RARE 2014
- Fundamental
- Price
- HGV $44.86
- RARE $39.91
- Analyst Decision
- HGV Buy
- RARE Strong Buy
- Analyst Count
- HGV 9
- RARE 15
- Target Price
- HGV $46.44
- RARE $90.53
- AVG Volume (30 Days)
- HGV 838.5K
- RARE 1.1M
- Earning Date
- HGV 08-07-2025
- RARE 07-31-2025
- Dividend Yield
- HGV N/A
- RARE N/A
- EPS Growth
- HGV N/A
- RARE N/A
- EPS
- HGV 0.34
- RARE N/A
- Revenue
- HGV $4,446,000,000.00
- RARE $590,689,000.00
- Revenue This Year
- HGV $19.10
- RARE $18.94
- Revenue Next Year
- HGV $6.88
- RARE $28.93
- P/E Ratio
- HGV $131.46
- RARE N/A
- Revenue Growth
- HGV 17.40
- RARE 33.46
- 52 Week Low
- HGV $30.59
- RARE $29.59
- 52 Week High
- HGV $45.53
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- HGV 75.50
- RARE 65.02
- Support Level
- HGV $41.22
- RARE $35.51
- Resistance Level
- HGV $41.42
- RARE $38.19
- Average True Range (ATR)
- HGV 1.09
- RARE 1.58
- MACD
- HGV 0.47
- RARE 0.20
- Stochastic Oscillator
- HGV 91.08
- RARE 98.43
About HGV Hilton Grand Vacations Inc.
Hilton Grand Vacations Inc is a timeshare company engaged in developing, marketing, selling, managing, and operating timeshare resorts, timeshare plans, and ancillary reservation services, under the Hilton Grand Vacations brand. The company operates business in the following two segments: (i) Real estate sales and financing and (ii) Resort operations and club management. The majority of the company's revenue is earned through the Real estate sales and financing segment, which generates revenue from VOI sales, and Financing.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.